$PEPG

PepGen advances Phase 2 study with 10 mg/kg DM1 cohort under way

PepGen announced positive data from the 5 mg/kg cohort of its Phase 2 FREEDOM2 MAD study for PGN-EDODM1, a treatment for myotonic dystrophy type 1 (DM1). These results support the ongoing evaluation of the 10 mg/kg cohort, with data expected in the latter half of 2026. The company is also scheduled to discuss these developments in an upcoming webcast and recently participated in the MDA2026 conference.

Original reporting
Traders Union · Hanna Syniavska
Published Mar 31, 2026, 2:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 31, 2026, 2:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PepGen advances Phase 2 study with 10 mg/kg DM1 cohort under way — source image
Decision brief

The 30-second read

$PEPGBullishMed
01

Why it matters

Positive trial data can boost investor confidence and stock valuation, but market reaction depends on data robustness and timing.

02

Market read

The news is relevant to biotech investors, particularly those interested in gene therapy and neuromuscular disorder treatments.

03

What to watch

Regulatory hurdles or funding issues could impact the company's progress regardless of trial data.

Timing: Upcoming data releases in H2 2026 are critical; traders should monitor for catalysts.

Background

PepGen is developing therapies for neuromuscular disorders, with PGN-EDODM1 showing promise in early trials.

Company-level read

Ticker impact

$PEPGBullishMedium confidence
Context

The news pertains to PepGen's ongoing Phase 2 clinical trial for DM1, indicating potential positive developments for the company's stock.

Expected impact

Moderate upward movement expected upon positive data release, with potential for short-term gains.

Evidence & confidence

Clinical trial progress can influence stock prices; however, the impact depends on the magnitude of the data and market perception.

Market effects

Advancement in DM1 treatments may positively influence the biotech sector focused on neuromuscular disorders.

Limited regional impact; primarily relevant to biotech investors and stakeholders.

Moderate; reflects ongoing innovation in gene and molecular therapies.

Counterpoint

Negative trial results or delays could lead to stock declines, offsetting potential gains.

Key entities

  • PepGen

    Biotech firm focused on gene therapy for neuromuscular diseases.

Related articles

$PEPGMed

PepGen Inc. (PEPG): Results of Operations and Financial Condition

PepGen Inc. (PEPG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pepg-ex99_1.htm EX-99.1 EX-99.1 PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights – DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg t

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.